Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Collegium Pharmaceutical ( (COLL) ) has issued an announcement.
On May 7, 2026, Collegium reported first-quarter 2026 net product revenue of $193.5 million, up 9% year over year, driven by 36% growth in JORNAY PM revenue to $38.9 million and 4% growth in its pain portfolio to $154.6 million. The company posted GAAP net income of $14.5 million versus $2.4 million a year earlier, generated $103.9 million in adjusted EBITDA, and ended the quarter with $421.8 million in cash, cash equivalents and marketable securities.
During the quarter ended March 31, 2026, Collegium advanced its ADHD strategy with record JORNAY PM prescriptions, expanded sales and marketing efforts, and a March agreement to acquire AZSTARYS for $650 million, with additional potential milestone payments and expected immediate adjusted EBITDA accretion upon closing in the second quarter. The company also highlighted stable growth across its pain brands, reaffirmed full-year 2026 guidance for revenues and adjusted EBITDA excluding AZSTARYS, and announced planned board changes ahead of its May 14, 2026 annual meeting, underscoring continued focus on portfolio diversification and long-term shareholder value.
The most recent analyst rating on (COLL) stock is a Hold with a $44.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.
Spark’s Take on COLL Stock
According to Spark, TipRanks’ AI Analyst, COLL is a Neutral.
The score is held back primarily by weak technicals (clear downtrend and negative momentum) and balance-sheet risk from leverage, despite strong cash generation and a constructive earnings call with reaffirmed guidance and strong Jornay PM momentum. Valuation appears middling at ~21.6x earnings with no dividend yield provided.
To see Spark’s full report on COLL stock, click here.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on responsible pain management medications and a rapidly growing neuropsychiatry business. Its primary products include a pain portfolio led by Belbuca, Xtampza ER and the Nucynta franchise, and JORNAY PM, a differentiated treatment for ADHD that anchors its expanding ADHD portfolio and U.S. market presence.
Headquartered in Stoughton, Mass., Collegium targets patients with serious medical conditions through branded therapies and selective capital deployment. The company is positioning itself as a leading player in both pain and ADHD therapeutics, using JORNAY PM as its main growth driver while adding complementary assets to extend revenue durability into the late 2030s.
Average Trading Volume: 518,210
Technical Sentiment Signal: Buy
Current Market Cap: $1.18B
For detailed information about COLL stock, go to TipRanks’ Stock Analysis page.